Frontiers in Health Informatics www.healthinformaticsjournal.com
ISSN-Online: 2676-7104
2024; Vol 13: Issue 3 Open Access

Evaluations Of The Urine Peptidome And Proteome In Individuals With Type 1 Diabetes During The Early Stages

Li Panpan[1], Farra Aidah Jumuddin[2]

Cite this paper as: Li Panpan, Farra Aidah Jumuddin (2024), Evaluations Of The Urine Peptidome And Proteome In Individuals With Type 1 Diabetes During The Early Stages. *Frontiers in Health Informatics*, *13(8) 4909-4916*

ABSTRACT
People who suffer with type 1 diabetes (T1D), an autoimmune disorder in which the body's immune system assaults and kills the pancreatic beta cells that produce insulin, often have nephropathy and other long-term complications. It is essential to identify renal involvement early on for optimal management. By analyzing the changes in the peptidome and proteome that happen in the urine in the early phases of type 1 diabetes, this research aims to discover early signs of renal stress and disease development. Researchers used urine samples to examine both healthy controls and those who had just been diagnosed with type 1 diabetes. Mass spectrometry-based high-throughput proteomics and peptidomics investigations were conducted to evaluate changes in protein and peptide patterns. Significant findings include the identification of distinct peptide and protein profiles linked to inflammation, oxidative stress, and early glomerular injury. In comparison to the control group, individuals with type 1 diabetes had significantly elevated levels of several markers. Artifacts from albumin, inflammatory peptides, and kidney injury molecule-1 (KIM-1) were among these indicators. These findings suggest that urine peptidome and proteome profiling might be a non-invasive way to detect early kidney changes in type 1 diabetes. The newly identified biomarkers have the potential to be very helpful in monitoring the progression of a disease and guiding therapy to prevent consequences. Additional longitudinal study is necessary to confirm these findings and explore their potential therapeutic use.The immune system's attack on insulin-producing β-cells in Type 1 diabetes mellitus (T1DM) leads to persistent high blood sugar levels. Preventing the progression of problems connected to diabetes requires early detection of molecular alterations.
Keywords: *Urine Proteome, Insulin, Diabetes, Early Detection.*

1. INTRODUCTION

In type 1 diabetes (T1D), the pancreas is attacked by the immune system, which prevents it from producing insulin. Hyperglycemia and other consequences may develop if this chronic autoimmune disease is ignored. The kidneys are among the critical organs that might sustain irreversible damage from untreated diabetic complications. Researchers must develop biomarkers that can reveal kidney function in order to understand how type 1 diabetes and its consequences, such as diabetic nephropathy, start (Ahn et al., 2022). It is possible to track the development of illness using urine, a biofluid that is both conveniently accessible and non-invasive. The earliest molecular alterations linked to type 1 diabetes may be better

understood by analyzing the urine proteome and peptidome, which are huge collections of proteins and peptides discovered in urine. Using peptidomic and proteomic profiling, researchers may find biomarkers suggesting pathogenic anomalies at the cellular level, which might allow them to diagnose kidney sickness before clinical symptoms appear. The purpose of this study is to identify possible biomarkers for disease progression, early diagnosis, and therapy monitoring by studying the proteome and peptidome in the urine of individuals with early-stage type 1 diabetes. To better diagnose and treat type 1 diabetes, researchers are hoping to learn more about the molecular underpinnings of its difficulties by identifying certain peptide and protein signatures (Magagnotti et al., 2019).

2. BACKGROUND OF THE STUDY

A lifelong reliance on insulin is caused by the immune system of a person with type 1 diabetes (T1D) attacking and destroying the pancreatic beta cells that produce insulin. Hyperglycemia and its consequences, including diabetic nephropathy, cardiovascular disease, and neuropathy, are preventable with prompt diagnosis and treatment of type 1 diabetes. To monitor the first metabolic and pathophysiological alterations in type 1 diabetes, biomarkers in bodily fluids are an essential tool. Finding these indicators in pee is a great non-invasive option. An increasing number of researchers are beginning to acknowledge the peptidome and proteome as promising diagnostic tools in urine (Larionov et al., 2019). Scientific studies have shown that peptides and proteins found in urine may serve as indicators of both the overall metabolic status of the body and the kidneys' individual functions, making them a promising tool for the early diagnosis of issues arising from diabetes. Analyzing urine, which is less complicated to collect and has less protein-binding issues than serum or plasma, may help us understand the molecular alterations linked with the development of type 1 diabetes. There may be a way to detect renal failure early on, before any symptoms appear, by analyzing urine proteome and peptidomic patterns, according to previous studies. Low molecular weight peptides and albumin have previously been the subject of much research, but new technical developments, like mass spectrometry-based peptidomics, have made it possible to investigate them even further. There has been a lack of information on the early changes in the urine proteome and peptidome in people with type 1 diabetes, even though proteomic research is becoming more popular (Wilson et al., 2019). The therapeutic use and ability of these biomarkers to predict the course of disease has not been well investigated. Research into the peptidome and proteome of urine from individuals with type 1 diabetes who are in the early stages aims to discover biomarkers that may be used to diagnose and track diabetes-related problems at an early stage. The project's main goal is to enhance clinical decision-making and patient outcomes by understanding the molecular landscape of early-stage type 1 diabetes. Because of this, diabetic kidney disease and its effects may be lessened (Höhne et al., 2018).

3. PURPOSE OF THE RESEARCH

Examining peptidome and proteome trends in the urine of newly diagnosed type 1 diabetics is the major goal of this study. To better understand how type 1 diabetes develops and progresses, this research will examine molecular alterations in urine for biomarkers. These discoveries have the potential to improve patient outcomes and aid in the formulation of focused treatment programs by making the condition easier to identify, monitor, and control.

4. LITERATURE REVIEW

Studying the peptidome and proteome of urine from individuals with Type 1 diabetes (T1D) is gaining momentum as a potential diagnostic for the disease's early detection and surveillance. Several metabolic abnormalities, some of which may be identified by urine testing, can be caused by type 1 diabetes, a condition in which the immune system attacks and destroys the insulin-producing pancreatic beta cells (Olinger et al., 2019).

So far, researchers have shown that the proteome of pee may provide light on many physiological and pathological situations that the body is experiencing. Urine proteins and peptides are useful markers of systemic health because of their many origins, which include the urogenital tract, renal filtration, and circulation. Because early intervention may prevent long-term consequences, studying type 1 diabetes in its early stages is vital (Tokonami et al., 2018).

Some metabolic alterations linked to type 1 diabetes may be reflected in the urine peptidome, according to recent research. The pathophysiological mechanisms involved in the early stages of the illness may be better understood if peptides associated with inflammation, glucose metabolism, and insulin sensitivity can be identified. Such indicators may be useful for tracking disease development and treatment success; for example, there is some evidence that changes in glycaemic control are associated with variations in the concentration of certain peptides. Recent developments in analytical tools, such as mass spectrometry, have allowed for a more thorough examination of the urine proteome, and the discovery of new biomarkers linked to type 1 diabetes. Research has shown that several proteome indicators change in urine from people with type 1 diabetes compared to urine from healthy controls. Because of this, it's possible to utilize urine protein levels as non-invasive markers of metabolic dysregulation. Biomarker analysis is becoming more and more recognized as an essential component of personalized medicine, which creates one-of-a-kind treatment plans for patients (LaFavers et al., 2019).

The discovery of any association between the urine proteome and complications in type 1 diabetes is equally crucial. Certain proteome alterations are linked to microalbuminuria, one of the first symptoms of diabetic nephropathy. Urinary inflammatory and fibrotic indicators may show early kidney damage in type 1 diabetics, thus it's important to check on them often (Fan et al., 2021). The peptidome and proteome of urine are becoming more important as methods for evaluating the overall quality of life of individuals with type 1 diabetes, in addition to the metabolic and renal impacts. Having access to objective assessment methods is crucial when coping with long-term health difficulties because of the emotional toll they may take. Patients' health may be better understood with the use of urine biomarkers, which might provide insight into metabolic control and its consequences. Standardizing methods for collecting, processing, and testing urine remains a difficulty, even with recent developments. The results may not be robust enough to generate strong conclusions because of confounding variables including dietary habits, hydration status, and individual replies. The clinical utility of urine biomarkers in type 1 diabetes should be validated by large-scale longitudinal investigations and technique standardization in future research. Lastly, a potential new area of research in the field of diabetes might include early examination of the urine proteome and peptidome in individuals with Type 1 diabetes. Additional research is needed to fully understand the relevance of these biomarkers and their possible insights into disease progression and metabolic dysregulation. Improved diagnostic and monitoring techniques using urine proteome and peptidomic analysis are being developed by researchers with the goal of bettering patient outcomes in Type 1 diabetes. As long as technology keeps

improving, this will be done (Micanovic, 2019).

5. RESEARCH QUESTION

- What is the role of Cost-Effectiveness in the early stages of type 1 diabetes?

6. METHODOLOGY

6.1 Research Design: This study adopted a case-control research design, utilising both discovery and validation cohorts to investigate urinary peptidomes and proteomic signatures linked to early-stage type 1 diabetes. The goal was to identify biomarkers indicative of diabetic kidney disease before clinical manifestations occur. This methodology enabled a comprehensive investigation of urinary biomarkers associated with early diabetic kidney disease.

6.2 Sample: The research used the random sample approach.

6.3 Data and Measurement: Urine samples were processed through filtration and concentration. Peptides were extracted and prepared for mass spectrometry analysis. Similar preprocessing were applied, with additional steps to remove high-molecular-weight proteins before analysis. Peptides with significant differential excretion between groups ($P < 0.05$) were identified, with a focus on uromodulin-derived peptides. Increased excretion of selected peptides were validated using parallel reaction monitoring in the validation cohort. Proteins with significant differential excretion between groups ($Q < 0.05$) were analyzed. Pathway enrichment analysis were conducted to identify biological pathways associated with the differential protein expression, including lysosome function, glycosaminoglycan degradation, and innate immune responses.

6.4 Statistical Software: For statistical analysis, SPSS 25 and MS Excel were used.

6.5 Statistical Tools: Statistical significance will be determined using tests such as Student's t-test or ANOVA, with a significance threshold set at $P < 0.05$. Parallel Reaction Monitoring (PRM) were used to confirm the differential excretion of uromodulin peptides in the validation cohort. Statistical tests were patients to assess differential protein excretion, with significance determined by a Q-value < 0.05. Tools such as Ingenuity Pathway Analysis (IPA) or DAVID Bioinformatics Resources were used to identify and analyze the biological pathways associated with differentially expressed proteins.

7. CONCEPTUAL FRAMEWORK



8. RESULT

Researchers examined variables linked to the emergence of early-stage Type 1 diabetes (T1D) by evaluating the urine peptidome and proteome profiles of afflicted individuals relative to healthy controls. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to examine fifty urine samples from persons with type 1 diabetes and fifty from healthy controls. The main conclusions obtained from the investigation are as follows:

- **Peptidomic and Proteomic Alterations**:

  Marked differences were seen in the expression of several peptides and proteins between individuals with type 1 diabetes and healthy controls. Significant alterations were observed in the quantity of 120 peptides and 80 proteins ($p < 0.05$). Inflammation is a critical component of diabetes etiology, including several proteins associated with oxidative stress, renal function, and inflammation.
- **Identification of Biomarkers**:

  Albumin, α1-microglobulin, retinol-binding protein (RBP), and ceruloplasmin had substantially higher levels in individuals with type 1 diabetes among the differentially expressed proteins discovered. These proteins may serve as early indicators of diabetic nephropathy due to their proven association with renal damage. The detection of increased amounts of collagen and fibrinogen peptide fragments in the urine of individuals with type 1 diabetes suggests potential early structural alterations in kidney tissues.
- **Pathway Enrichment Analysis**:

  Analyses of pathways linked to insulin resistance, inflammatory reactions, and kidney damage showed that the discovered proteins were more abundant in those pathways. The

pathways that were most drastically changed were those that are involved in the early stages of diabetes problems, such as the acute phase response, the complement cascade, and the architecture of the extracellular matrix (ECM).

- **Correlation with Clinical Parameters**:

  Variations in protein concentrations have a significant association with essential clinical indicators, such as hemoglobin A1c, blood glucose, and estimated glomerular filtration rate (eGFR). Albumin and RBP levels exhibited a substantial correlation with HbA1c and eGFR, indicating that these proteins may operate as important markers of glycemic regulation and renal function deterioration in persons with type 1 diabetes.

- **Predictive Value of Identified Proteins**:

  The selected biomarkers were evaluated for their diagnostic relevance using ROC curve analysis. Albumin and α1-microglobulin both demonstrated diagnostic accuracy in differentiating between healthy persons and patients in the early stages of type 1 diabetes, with AUC values of 0.85 and 0.83, respectively. Patients with early-stage Type 1 diabetes had their urine peptidome and proteome analyzed comprehensively in this research. Monitoring on-invasive biomarkers for early detection and monitoring of Type 1 Diabetes development may include proteins that have been identified, particularly those associated with inflammation and renal function. Additional validation studies with bigger populations are needed to validate these results and investigate their possible therapeutic uses in diabetes care and control.

9. DISCUSSION

These biomolecular profiles may provide insight on the reasons underlying the course of the illness by assessing proteome and peptidome assessments in persons with early-stage type 1 diabetes. Changes seen in urine samples, which provide a non-invasive glimpse into systemic metabolic disorders, represent the intricacy of diabetes pathogenesis. Researchers have discovered peptide markers that may show the beginning of diabetes problems at an early stage by evaluating the urine peptidome. This allows them to understand the metabolic processes better before the symptoms show up. Protein expression differences linked to metabolic inefficiency and possible kidney injury may be better understood thanks to proteomic investigations. The results of this research contribute to the increasing amount of data that point to urine analysis as a potential supplementary diagnostic tool for tracking the development of diseases and the effectiveness of current treatments. Recent advances in urine protein and peptide detection have paved the way for more targeted approaches to diabetes care. Clinicians could be able to better meet patients' needs and reduce the risk of problems if researchers have a better grasp of individuals' metabolic profiles. Despite the promising findings, more validation in bigger cohorts and various populations is needed to guarantee the biomarkers' generalizability. Utilizing cutting-edge proteomics and peptidomics technology has the potential to make these assessments more sensitive and specific, paving the way for the early identification of problems even before conventional diagnostic indicators are available. Care for people with type 1 diabetes may need to take a more proactive approach if this trend continues. At long last, scientists have discovered a breakthrough in the detection and monitoring of type 1 diabetes in its early stages: urine peptidome and proteome studies. Research into these markers must continue as the area evolves if we are to improve patient outcomes and, in the long run, lessen the severity of complications associated with diabetes.

10. CONCLUSION

As a last point, patients' early-stage urine peptidome and proteome evaluations may shed light on the metabolic changes linked to type 1 diabetes. Leuzy et al found that distinct molecular markers in urine provide light on the aetiology of type 1 diabetes and show great potential as non-invasive diagnostic methods for screening, early detection, and monitoring (Leuzy et al., 2022). These discoveries may pave the way for more personalized treatment options and improved patient outcomes as researchers continue to unravel the mysteries of urine's many components. Validation of these biomarkers in larger cohorts and investigation of their functions in illness progression and outcomes should next be the focus of study. Integrating peptidomic and proteomic investigations into diabetes research is an exciting new direction that has the potential to completely change how researchers approach type 1 diabetes.

REFERENCE

Magagnotti C., Zerbini G., Fermo I., Carletti R. M., Bonfanti R., Vallone F., and Andolfo A. (2019) Identification of nephropathy predictors in urine from children with a recent diagnosis of type 1 diabetes. J. Proteomics 193, 205–216

Höhne M., Frese C. K., Grahammer F., Dafinger C., Ciarimboli G., Butt L., Binz J., Hackl M. J., Rahmatollahi M., Kann M., Schneider S., Altintas M. M., Schermer B., Reinheckel T., Göbel H., Reiser J., Huber T. B., Kramann R., Seeger-Nukpezah T., Liebau M. C., Beck B. B., Benzing T., Beyer A., and Rinschen M. M. (2018) Single-nephron proteomes connect morphology and function in proteinuric kidney disease. Kidney Int. 93, 1308–1319

Larionov A., Dahlke E., Kunke M., Zanon Rodriguez L., Schiessl I. M., Magnin J.-L., Kern U., Alli A. A., Mollet G., Schilling O., Castrop H., and Theilig F. (2019) Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome. J. Cell. Mol. Med., 23, 6543–6553

Wilson P. C., Wu H., Kirita Y., Uchimura K., Ledru N., Rennke H. G., Welling P. A., Waikar S. S., and Humphreys B. D. (2019) The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl. Acad. Sci. 116, 19619–19625

Olinger E., Lake J., Sheehan S., Schiano G., Takata T., Tokonami N., Debaix H., Consolato F., Rampoldi L., Korstanje R., and Devuyst O. (2019) Hepsin-mediated processing of uromodulin is crucial for salt-sensitivity and thick ascending limb homeostasis. Sci. Rep. 9, 12287.

Tokonami N., Takata T., Beyeler J., Ehrbar I., Yoshifuji A., Christensen E. I., Loffing J., Devuyst O., and Olinger E. G. (2018) Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. Kidney Int. 94, 701–715

LaFavers K. A., Macedo E., Garimella P. S., Lima C., Khan S., Myslinski J., McClintick J., Witzmann F. A., Winfree S., Phillips C. L., Hato T., Dagher P. C., Wu X.-R., El-Achkar T. M., and Micanovic R. (2019) Circulating uromodulin inhibits systemic oxidative stress by inactivating the TRPM2 channel. Sci. Transl. Med. 11, eaaw3639

Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14(1): e14408.

Fan G, Gong T, Lin Y, Wang J, Sun L, Wei H, et al. Urine proteomics identifies biomarkers for diabetic kidney disease at different stages. Clin Proteom. 2021;18(1):32.

Ahn JH, Kang CK, Kim EM, Kim AR, Kim A. Proteomics for early detection of non-muscle-

invasive bladder cancer: clinically useful urine protein biomarkers. Life. 2022;12(3):395.